Why Aciclovir is Not Effective Against CMV
Aciclovir is not effective against CMV because CMV lacks the viral-encoded thymidine kinase (TK) enzyme that is essential for activating aciclovir into its active triphosphate form.
Mechanism of Aciclovir's Selectivity
Aciclovir's antiviral activity depends on a critical two-step activation process 1:
- Viral thymidine kinase converts aciclovir to aciclovir monophosphate - This is the rate-limiting step that provides selectivity
- Cellular enzymes then convert the monophosphate to diphosphate and triphosphate forms
- Aciclovir triphosphate then inhibits viral DNA polymerase
The problem with CMV: Unlike HSV-1, HSV-2, and VZV (which all encode their own thymidine kinase), CMV does not produce this viral TK enzyme 1, 2. Without viral TK, aciclovir cannot be efficiently phosphorylated to its active form, rendering it ineffective at clinically achievable concentrations.
Clinical Evidence of Ineffectiveness
Multiple authoritative guidelines explicitly state aciclovir's lack of efficacy against CMV:
The 1999 USPHS/IDSA guidelines clearly state: "Acyclovir is not effective in preventing CMV disease" and recommend against its use for CMV prophylaxis (EI recommendation - evidence against use) 3
The 2009 guidelines reiterate this position, noting that while oral valganciclovir (a prodrug of ganciclovir, not aciclovir) would likely prevent CMV retinitis, such therapy is not usually recommended 4
In Vitro Activity Does Not Translate Clinically
While some research shows that aciclovir can inhibit CMV in vitro, this occurs only at very high concentrations (100-200 μM or 10-25 mg/L) that are not achievable or safe in clinical practice 5, 6, 7:
- Recent 2025 data confirms that both aciclovir and valaciclovir have poor anti-CMV activity compared to ganciclovir, with robust inhibition only at high drug concentrations 8
- The IC₅₀ values for aciclovir against CMV are 50-100 times higher than those for HSV
- Even at 200 μM, complete inhibition of CMV plaque formation is rarely achieved 6
Spectrum of Aciclovir Activity
The FDA label clearly defines aciclovir's antiviral spectrum 1:
- Greatest activity: HSV-1 and HSV-2 (IC₅₀: 0.01-13.5 mcg/mL)
- Moderate activity: VZV (IC₅₀: 0.12-10.8 mcg/mL)
- Minimal activity: Epstein-Barr virus
- Very little activity: CMV
This hierarchy directly correlates with the efficiency of viral TK-mediated phosphorylation - VZV has less efficient TK than HSV, explaining why higher aciclovir doses are needed for VZV infections 2.
Clinical Implications
For CMV prophylaxis and treatment, effective agents include:
- Ganciclovir/valganciclovir (first-line)
- Foscarnet
- Cidofovir
- Maribavir (for resistant/refractory cases)
- Letermovir (prophylaxis in high-risk patients)
These agents work through TK-independent mechanisms or are substrates for CMV's UL97 kinase (in the case of ganciclovir), making them effective where aciclovir fails 3, 4, 9, 10.
Common pitfall: Do not confuse valaciclovir (prodrug of aciclovir) with valganciclovir (prodrug of ganciclovir). Despite similar names, only valganciclovir is effective against CMV. The 1999 guidelines specifically warn against using valaciclovir for CMV prophylaxis due to an unexplained trend toward increased mortality 3.